Browse > Article
http://dx.doi.org/10.5483/BMBRep.2010.43.2.146

Induction of insulin receptor substrate-2 expression by Fc fusion to exendin-4 overexpressed in E. coli: a potential long-acting glucagon-like peptide-1 mimetic  

Kim, Jae-Woo (Department of Molecular Biology, Daegu University)
Kim, Kyu-Tae (Department of Molecular Biology, Daegu University)
Ahn, You-Jin (Gyeongsan Science High School)
Jeong, Hee-Jeong (Gyeongsan Science High School)
Jeong, Hyeong-Yong (Gyeongsan Science High School)
Ryu, Seung-Hyup (Gyeongsan Science High School)
Lee, Seung-Yeon (Gyeongsan Science High School)
Lee, Chang-Woo (Department of Molecular Biology, Daegu University)
Chung, Hye-Shin (Department of Biotechnology, Hannam University)
Jang, Sei-Heon (Department of Molecular Biology, Daegu University)
Publication Information
BMB Reports / v.43, no.2, 2010 , pp. 146-149 More about this Journal
Abstract
Exendin-4 (Ex-4), a peptide secreted from the salivary glands of the Gila monster lizard, can increase pancreatic $\beta$-cell growth and insulin secretion by activating glucagon-like peptide-1 receptor. In this study, we expressed a fusion protein consisting of exendin-4 and the human immunoglobulin heavy chain (Ex-4/IgG-Fc) in E. coli and explored its potential therapeutic use for the treatment of insulin-resistant type 2 diabetes. Here, we show that the Ex-4/IgG-Fc fusion protein induces expression of insulin receptor substrate-2 in rat insulinoma INS-1 cells. Our findings therefore suggest that Ex-4/IgG-Fc overexpressed in E. coli could be used as a potential, long-acting glucagon-like peptide-1 mimetic.
Keywords
Exendin-4; Glucagon-like peptide-1; Insulin receptor substrate-2; Type 2 diabetes;
Citations & Related Records
Times Cited By KSCI : 1  (Citation Analysis)
Times Cited By Web Of Science : 0  (Related Records In Web of Science)
Times Cited By SCOPUS : 0
연도 인용수 순위
1 Giannoukakis, N. (2003) Exenatide. Amylin/Eli Lilly. Curr. Opin. Investig. Drugs. 4, 459-465   PUBMED
2 Xu, G., Stoffers, D. A., Habener, J. F. and Bonner-Weir, S. (1999) Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48, 2270-2276   DOI   ScienceOn
3 Deacon, C. F., Johnsen, A. H. and Holst, J. J. (1995) Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J. Clin. Endocrinol. Metab. 80, 952-957   DOI   ScienceOn
4 Schmidt, S. R. (2009) Fusion-proteins as biopharmaceuticals - applications and challenges. Curr. Opin. Drug. Discov. Devel. 12, 284-295   PUBMED
5 Jhala, U. S., Canettieri, G., Screaton, R. A., Kulkarni, R. N., Krajewski, S., Reed, J., Walker, J., Lin, X., White, M. and Montminy, M. (2003) cAMP promotes pancreatic b-cell survival via CREB-mediated induction of IRS2. Genes Dev. 17, 1575-1580   DOI   ScienceOn
6 Leahy, D. J., Dann, C. E., 3rd, Longo, P., Perman, B. and Ramyar, K. X. (2000) A mammalian expression vector for expression and purification of secreted proteins for structural studies. Protein Expr. Purif. 20, 500-506   DOI   ScienceOn
7 Hui, H., Nourparvar, A., Zhao, X. and Perfetti, R. (2003) Glucagon-like peptide-1 inhibits apoptosis of insulin- secreting cells via a cyclic 5'-adenosine monophosphatedependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144, 1444-1455   DOI   ScienceOn
8 Park, S., Dong, X., Fisher, T. L., Dunn, S., Omer, A. K., Weir, G. and White, M. F. (2006) Exendin-4 uses Irs2 signaling to mediate pancreatic beta cell growth and function. J. Biol. Chem. 281, 1159-1168   DOI   ScienceOn
9 Soltani, N., Kumar, M., Glinka, Y., Prud'homme, G. J. and Wang, Q. (2007) In vivo expression of GLP-1/IgG-Fc fusion protein enhances beta-cell mass and protects against streptozotocin-induced diabetes. Gene Ther. 14, 981-988   DOI   ScienceOn
10 Parkes, D., Jodka, C., Smith, P., Nayak, S., Rinehart, L., Gingerich, R., Chen, K. and Young, A., (2001) Pharmacokinetic actions of exendin-4 in the rat: Comparison with glucagon-like peptide-1. Drug. Dev. Res. 54, 260-267
11 Kumar, M., Hunag, Y., Glinka, Y., Prud'homme, G. J. and Wang, Q. (2007) Gene therapy of diabetes using a novel GLP-1/IgG1-Fc fusion construct normalizes glucose levels in db/db mice. Gene Ther. 14, 162-172   PUBMED
12 Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E. and Maggs, D. G. (2008) Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr. Med. Res. Opin. 24, 275-286   DOI   PUBMED
13 Kim, D. M., Chu, S. H., Kim, S., Park, Y. W. and Kim, S. S. (2009) Fc fusion to glucagon-like peptide-1 inhibits degradation by human DPP-IV, increasing its half-life in serum and inducing a potent activity for human GLP-1 receptor activation. BMB Rep. 42, 212-216   DOI   PUBMED   ScienceOn
14 Huang, Y. S., Chen, Z., Chen, Y. Q., Ma, G. C., Shan, J. F., Liu, W. and Zhou, L. F. (2008) Preparation and characterization of a novel exendin-4 human serum albumin fusion protein expressed in Pichia pastoris. J. Pept. Sci. 14, 588-595   DOI   ScienceOn
15 White, M. F. (2003) Insulin signaling in health and disease. Science 302, 1710-1711   DOI   PUBMED   ScienceOn
16 Eng, J., Kleinman, W. A., Singh, L., Singh, G. and Raufman, J. P. (1992) Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J. Biol. Chem. 267, 7402-7405   PUBMED